Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury - PubMed (original) (raw)
Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury
T Sawa et al. Nat Med. 1999 Apr.
Abstract
Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause fatal acute lung infections in critically ill individuals. Damage to the lung epithelium is associated with the expression of toxins that are directly injected into eukaryotic cells through a type Ill-mediated secretion and translocation mechanism. Here we show that the P. aeruginosa homolog of the Yersinia V antigen, PcrV, is involved in the translocation of type III toxins. Vaccination against PcrV ensured the survival of challenged mice and decreased lung inflammation and injury. Antibodies to PcrV inhibited the translocation of type III toxins.
Comment in
- For Pseudomonas aeruginosa, stealth is no longer enough.
Brubaker RR. Brubaker RR. Nat Med. 1999 Apr;5(4):378-9. doi: 10.1038/7372. Nat Med. 1999. PMID: 10202921 No abstract available.
Similar articles
- Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K, Wiener-Kronish JP, Sawa T. Moriyama K, et al. Microbiol Immunol. 2009 Nov;53(11):587-94. doi: 10.1111/j.1348-0421.2009.00165.x. Microbiol Immunol. 2009. PMID: 19903258 - Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
Neely AN, Holder IA, Wiener-Kronish JP, Sawa T. Neely AN, et al. Burns. 2005 Mar;31(2):153-8. doi: 10.1016/j.burns.2004.09.002. Burns. 2005. PMID: 15683685 - PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
Wang Q, Li H, Zhou J, Zhong M, Zhu D, Feng N, Liu F, Bai C, Song Y. Wang Q, et al. Respir Physiol Neurobiol. 2014 Mar 1;193:21-8. doi: 10.1016/j.resp.2014.01.001. Epub 2014 Jan 10. Respir Physiol Neurobiol. 2014. PMID: 24418353 - Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G. Pier G. Expert Rev Vaccines. 2005 Oct;4(5):645-56. doi: 10.1586/14760584.4.5.645. Expert Rev Vaccines. 2005. PMID: 16221066 Review. - V-antigen homologs in pathogenic gram-negative bacteria.
Sawa T, Katoh H, Yasumoto H. Sawa T, et al. Microbiol Immunol. 2014 May;58(5):267-85. doi: 10.1111/1348-0421.12147. Microbiol Immunol. 2014. PMID: 24641673 Review.
Cited by
- High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement.
De Tavernier E, Detalle L, Morizzo E, Roobrouck A, De Taeye S, Rieger M, Verhaeghe T, Correia A, Van Hegelsom R, Figueirido R, Noens J, Steffensen S, Stöhr T, Van de Velde W, Depla E, Dombrecht B. De Tavernier E, et al. J Biol Chem. 2016 Jul 15;291(29):15243-55. doi: 10.1074/jbc.M115.684241. Epub 2016 May 20. J Biol Chem. 2016. PMID: 27226529 Free PMC article. - Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.
DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, Wang Q, Keller AE, Bonnell JC, Tomich M, Jermutus L, McCarthy MP, Melnick DA, Suzich JA, Stover CK. DiGiandomenico A, et al. J Exp Med. 2012 Jul 2;209(7):1273-87. doi: 10.1084/jem.20120033. Epub 2012 Jun 25. J Exp Med. 2012. PMID: 22734046 Free PMC article. - Baicalin Represses Type Three Secretion System of Pseudomonas aeruginosa through PQS System.
Zhang P, Guo Q, Wei Z, Yang Q, Guo Z, Shen L, Duan K, Chen L. Zhang P, et al. Molecules. 2021 Mar 10;26(6):1497. doi: 10.3390/molecules26061497. Molecules. 2021. PMID: 33801847 Free PMC article. - Orientation of Pseudomonas aeruginosa ExsA monomers bound to promoter DNA and base-specific contacts with the P(exoT) promoter.
King JM, Brutinel ED, Marsden AE, Schubot FD, Yahr TL. King JM, et al. J Bacteriol. 2012 May;194(10):2573-85. doi: 10.1128/JB.00107-12. Epub 2012 Mar 9. J Bacteriol. 2012. PMID: 22408167 Free PMC article. - Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system.
Numata S, Hara T, Izawa M, Okuno Y, Sato Y, Yamane S, Maki H, Sato T, Yamano Y. Numata S, et al. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0069424. doi: 10.1128/aac.00694-24. Epub 2024 Sep 13. Antimicrob Agents Chemother. 2024. PMID: 39269189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical